Boston Scientific buying cardiac health company Preventice Solutions in deal worth up to $1.2B

Boston Scientific Corp. said it has agreed to acquire Preventice Solutions Inc. for $925 million up front and up to an additional $300 million in a potential commercial milestone payment. The former has been an investor in Preventice since 2015 and currently holds an equity stake of about 22%, which is expected…